You are here
- Home
- drug and drug industry
drug and drug industry
- Off-label use of bevacizumab in the treatment of retinal disease: ethical implicationsLandon James RohowetzJournal of Medical Ethics Oct 2019, 45 (10) 668-672; DOI: 10.1136/medethics-2018-105286
- CLINICAL
- Anaesthesia
- Other anaesthesia (34)
- Pain (anaesthesia) (18)
- Diagnostics
- Evidence based practice
- Genetics
- Clinical genetics (36)
- Molecular genetics (10)
- Geriatric medicine
- Elder abuse (1)
- Long term care (10)
- Psychogeriatrics (13)
- Infectious diseases
- Intensive care
- Adult intensive care (67)
- Neurology
- Nursing (25)
- Obstetrics and gynaecology
- Abortion (18)
- Oncology (115)
- Paediatrics
- Child health (222)
- Palliative care
- Hospice (155)
- Prison medicine (45)
- Psychiatry
- Suicide (psychiatry) (160)
- Rehabilitation medicine
- Disability (71)
- Renal medicine
- Dialysis (1)
- Respiratory medicine
- Sexual health (194)
- NON-CLINICAL
- Communication (14)
- Epidemiology
- Epidemiologic studies (104)
- Ethics
- Assisted dying (249)
- Bioethics (215)
- Clinical ethics (96)
- Confidentiality (110)
- Drug issues (5)
- Ethics of abortion (206)
- Ethics of reproduction (375)
- Experiments in vivo (10)
- Informed consent (348)
- Health economics (50)
- Health policy (143)
- Health service research (118)
- Healthcare improvement and patient safety
- Medical careers
- Medical education
- Postgraduate (10)
- Undergraduate (133)
- Medical humanities
- Education, medical (72)
- History of medicine (14)
- Psychology and medicine (290)
- Sex and sexuality (206)
- Trust (4)
- Medical management
- Patients (85)
- Public health
- Health education (106)
- Human rights (194)
- Injury diagnoses
- Injury location
- Injury mechanisms
- Smoking (37)
- Suicide (public health) (160)
- Sociology (6)
- Special collections
- Editor's choice (122)
- JME DSM-5 (5)
- Open access (184)
- Press releases (63)
- Special issues